Metabolic and Pharmacokinetic Differentiation of STX209 and Racemic Baclofen in Humans
STX209 is an exploratory drug comprising the single, active R-enantiomer of baclofen which is in later stage clinical trials for the treatment of fragile x syndrome (FXS) and autism spectrum disorders (ASD). New clinical data in this article on the metabolism and pharmacokinetics of the R- and S-ena...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2012-09-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2218-1989/2/3/596 |